StockIQ.techMirum Pharmaceuticals, Inc. (MIRM) Stock Analysis
Free AI-powered analysis and research for Mirum Pharmaceuticals, Inc. stock
Sector: Healthcare
Full MIRM report
Mirum Pharmaceuticals, Inc. (MIRM) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze MIRM Now →📰 Latest Update
AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?
Sat, October 31, 2026 at 9:17 PM UTC 3 min read
AnaptysBio, Inc. (ANAB) has transitioned from a traditional biotech firm to a royalty-focused business, primarily generating income from its cancer drug Jemperli, which is expected to see significant sales growth. The company holds about $140 million in net cash and operates with minimal expenses, while a lawsuit against GlaxoSmithKline could enhance its royalty rates. Analysts suggest that as Jemperli's sales increase and a financial obligation to Sagard concludes, ANAB's cash flow and stock value could improve significantly.